MIND MEDICINE (MINDMED) INC.

(MNMD)
  Report
Delayed Nasdaq  -  05/27 04:00:01 pm EDT
0.8743 USD   +9.48%
05/26IIROC Trading Halt - MMED.WT
AQ
05/23Mind Medicine Names Schond Greenway as CFO
MT
05/23MindMed Appoints Schond L. Greenway as Chief Financial Officer
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mind Medicine Gets FDA Clearance for IND Application for Anxiety Treatment

01/25/2022 | 08:02am EDT

By Chris Wack


Mind Medicine Inc. said the U.S. Food and Drug Administration has cleared its investigational new-drug application, allowing the company's Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder to proceed.

The biopharmaceutical company said the previously announced clinical hold on the IND was lifted following its rapid responses for additional information related to the participant monitoring protocol in the coming study.

Mind Medicine said it is working with study investigators and clinical trial sites to prepare for participant enrollment, which is expected to start in early 2022.

Mind Medicine shares were up 16% to $1.08 in premarket trading.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

01-25-22 0802ET

All news about MIND MEDICINE (MINDMED) INC.
05/26IIROC Trading Halt - MMED.WT
AQ
05/23Mind Medicine Names Schond Greenway as CFO
MT
05/23MindMed Appoints Schond L. Greenway as Chief Financial Officer
PR
05/23Mind Medicine Inc. Appoints Schond L. Greenway as Chief Financial Officer
CI
05/19Mind Medicine Reports Positive Topline Data From Phase 1 Trial of Opioid Withdrawal Tre..
MT
05/19MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatm..
PR
05/19Mind Medicine Inc Reports Topline Data from Phase 1 Trial of MM-110 in Development for ..
CI
05/17Mind Medicine Expects to Raise $100 Million Through At-the-Market Offering
MT
05/16MindMed Announces At-The-Market Offering
AQ
05/16TRANSCRIPT : Mind Medicine Inc., Q1 2022 Earnings Call, May 16, 2022
CI
More news
Analyst Recommendations on MIND MEDICINE (MINDMED) INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -79,8 M - -
Net cash 2022 73,9 M - -
P/E ratio 2022 -4,60x
Yield 2022 -
Capitalization 370 M 370 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 41
Free-Float 87,5%
Chart MIND MEDICINE (MINDMED) INC.
Duration : Period :
Mind Medicine (MindMed) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIND MEDICINE (MINDMED) INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,87 $
Average target price 6,67 $
Spread / Average Target 663%
EPS Revisions
Managers and Directors
Robert Barrow Chief Executive Officer & Director
Miri Halperin Wernli Executive President & Director
Carol Ann Vallone Chairman
Daniel R. Karlin Chief Medical Officer
Madeline Feldman Director-Administration & Operations
Sector and Competitors
1st jan.Capi. (M$)
MIND MEDICINE (MINDMED) INC.-36.64%370
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478